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Two recent papers in PLoS Pathogens
have investigated the activity of antigen-
specific cells within the lung of mice
infected with Mycobacterium tuberculosis
(Mtb) [1,2]. To the uninitiated this may
seem to be redundant, as ‘‘we all know’’
that antigen-specific cells make interferon
gamma (IFNc) and tumor necrosis factor
(TNF), which activate infected phagocytes
to kill the bacteria. However, what we
really know is that IFNc and TNF are
essential for controlling both bacterial
growth and immunopathology and that
the acquired immune response is critical to
orchestrating immunity [3]. What we also
know is that cessation of bacterial growth
in the lungs correlates temporally with the
accumulation of IFNc-producing antigen-
specific T cells in the infected lung [3]. But
several questions have been circulating in
the field for some time, including, What
are effector T cells doing during tubercu-
losis to mediate protection, and How does
the environment within the granuloma
affect this activity? [3].
In the first of these stimulating PLoS
Pathogens papers, Gallegos et al. provided
compelling evidence that CD4 T cells can
induce Mtb growth arrest, even when
unable to secrete IFNc, TNF, or both
cytokines [1]. In the second paper, Bold
et al. showed that CD4 T cell activation
(as measured by production of IFNc)i s
suboptimal in the lungs of infected ani-
mals, and they suggest that this contributes
to the inability of the host to eliminate the
infection; they also link this low frequency
of T cell activation to the level of cognate
antigen in the lung [2].
In the paper by Gallegos et al., they
investigated the relevance of cytokine-
producing CD4 T cells during experimen-
tal Mtb infection by the transfer of T cell
receptor transgenic (TCR Tg) cells into
host mice. They found that growth arrest
over the first 21 days after aerosol
challenge occurred even when these cells
were unable to express the Th1-promoting
transcription factor T-bet or to secrete
IFNc, TNF, or both cytokines [1]. Of
equal importance was the fact that there
was no need for host IFNc, TNF, the
inducible nitric oxide synthase (iNOS)
gene, or superoxide-generating machinery
to mediate this control [1]. This antigen-
specific effect could be seen both with in
vitro expanded and polarized T cells as
well as, to a lesser degree, naive T cells [1].
In addition, the authors showed that this
was not a property of all in vitro–
generated cells, since Th2 differentiated
cells could not induce Mtb growth arrest
as efficiently as Th1 or even Th17
differentiated cells. While the mechanism
was not identified, previously published
data have shown that in vitro–generated
memory CD4 T cells enhance protection
in the flu model by induction of multiple
innate cytokines and chemokines in the
lung in an antigen-dependent, but IFNc
and TNF independent, manner [4]. An-
other possibility is that elevated precursor
frequency may dampen the activation of
antigen-specific regulatory T cells, and
indeed, the authors report that the adop-
tively transferred cells delayed the priming
of the endogenous response [1]. Recent
data have shown that regulatory T cells
are induced very early and can regulate
effector function in the aerosol Mtb
models [5]. Bold et al. considered the
importance of competition in their study
but were concerned that the endogenous
response was limiting the transferred
response as a result of competition or
regulatory activity—they found, however,
that depletion of half of the endogenous
cells within the lung did not result in
increased activation of the transferred
effector cells [2].
The ‘‘take home’’ message of the Bold
paper is that the frequency of cells that
produce IFNc is low, even at the peak of
the response, and that it decreases during
the chronic phase [2], supporting previous
work that suggested this pattern [6]. In the
Bold paper, just as in the Gallegos paper,
the authors transferred pre-activated anti-
gen-specific TCR Tg CD4 T cells and
used the expression of IFNc (assessed
directly ex vivo) as a marker of antigen
recognition. They showed that the fre-
quency of IFNc-producing cells correlated
with the availability of cognate antigen
and that delivery of the cognate peptide
resulted in greatly increased frequency of
cytokine expression [2]. They also saw a
modest decrease in bacterial numbers
when the antigen was either forcibly
expressed by the Mtb or if the antigen
was delivered exogenously to the infected
mice. Initiation of CD4 T cell responses
during tuberculosis occurs in the lung-
draining lymph nodes rather than in the
lung; however, the data by Bold et al.
support the hypothesis that CD4 T cells
need to see antigen once again within the
infection site to express their effector
function. Another recent paper, wherein
intravital multiphoton imaging was used to
compare the movement patterns and
effector function of pre-activated and
control TCR Tg CD4 T cells (from the
p25 mouse specific for Ag85 [7] also used
in [2]), has also shown that effector
function is poorly expressed in the gran-
uloma [8]. The authors made the surpris-
ing observations that both mycobacteria-
specific and non-specific CD4 T cell
migrated vigorously through the granulo-
ma, with very few antigen-specific T cells
showing migration arrest, a hallmark of
potent antigen recognition and presenta-
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tion, the antigen-specific cells reacted
differently to the antigen in the environ-
ment as they upregulated CD69, whilst the
control non-antigen-specific T cells did
not. As was seen in the Bold paper, there
was very little real-time expression of IFNc
within the granuloma in this model. These
data were taken to reflect the failure of the
available antigen to signal both migration
arrest and cytokine production by the
effector cell, and this was supported by the
fact that delivery of exogenous peptide
resulted in expression of these functions by
the antigen-specific cells within the gran-
uloma [8]. One exciting observation of
this work was that the cells that did exhibit
migration arrest could (but not always)
produce a targeted release of cytokine to a
closely adjacent infected cell; these data
suggest that the accepted protective mech-
anism of T cell–derived IFNc-mediation
of infected phagocyte activation does
occur in the granuloma.
However, putting these recent observa-
tions together, it is clear that the accepted
mechanism may not be all there is to the
control of Mtb. It would seem that
expression of full effector activity by
antigen-specific CD4 T cells within the
granuloma is constrained by antigen
availability and that there is the potential
for antigen-specific T cells to mediate their
effector function without the use of
cytokine. As we cannot currently measure
this effector function, other than by
bacterial arrest, we cannot discount the
possibility that the appropriate effector
function is being expressed, but that it does
not require significant migration arrest or
cytokine production (Figure 1).
Other factors to take into account when
thinking about the above papers is the
artificial nature of transferred TCR Tg T
cells, which may allow them to act
differently to endogenous responses. It is
also important to remember that specific
protective immune mechanisms have dif-
ferent levels of importance depending on
the potency of the bacterial challenge
(discussed in [9]). Most importantly, the
relative levels of specific mycobacterial
antigens, particularly Ag85, which is the
target of the TCR Tg cells used to assess
effector function in the granuloma [2,8],
change over time as a function of bacterial
physiology in the face of host immunity
[10,11]. These changes in bacterial activ-
ity will substantially impact the readout to
any one antigen, and it is therefore
important to investigate the activity of
cells specific for other antigen as well as to
measure activities other than IFNc pro-
duction. Despite the caveats, these papers
remind us that although bacterial growth
ceases within the resistant mouse model,
we still do not know quite how this occurs.
These recent excellent papers prompt us
to continue to investigate the microanat-
omy of T cell function within the granu-
loma and to not be content with ‘‘what we
know’’.
Finally, the key question is, how can this
information improve control of tuberculo-
sis? It is certainly critical to define the
protective effector functions of antigen-
specific T cells as well as to determine the
significance of suboptimal T cell activa-
tion. In this way we will be better able to
design more effective vaccines and to
determine whether the limited T cell
activation in the granuloma is a host
mechanism to cope with chronic infection
or a mechanism Mtb evolved to prevent
Figure 1. Effector T cells do not find the granuloma to be a stimulating environment. Effector T cells enter the granuloma and only a few
exhibit significant migration arrest (dark blue cells) and targeted release of IFNc, likely when they encounter a high level of cognate antigen on
infected phagocytes. As their cognate antigen is reduced, even fewer cells undergo migration arrest, with many more cells continuing to move
throughout the granuloma (light blue motile cells). Although these cells do not stop migrating, they do up regulate CD69 in an antigen-specific
manner. Cells entering the granuloma may mediate their effector function without the release of IFNc, and while this activity does require
recognition of antigen, it may not need migration arrest.
doi:10.1371/journal.ppat.1002196.g001
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ing to pursue the above goals, we will be
able to manipulate T cell responses in the
infection site to enhance their effector
function and to tip the balance of disease
in favor of the host with minimal immu-
nopathological consequences.
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